This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > DermaSys for erectile dysfunction

< Back

DermaSys for erectile dysfunction


Men's Health and Sexual Health

January 2020

DermaSys is in clinical development for treating erectile dysfunction (ED), which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance. ED is very common, particularly in men over the age of 40 years. It can be caused by any number of physical and psychological factors. Any abnormality involving the nervous, circulatory or hormonal systems, whether due to medication or disease, may affect the ability to develop and sustain an erection. Although ED is a benign disorder, it may affect physical and psychosocial health and may have a significant impact on the quality of life of sufferers and their partners.
DermaSys is a drug delivery technology platform that provides rapid and targeted local delivery of active pharmaceutical ingredients (API) at therapeutic levels to the required site of action. If licensed, DermaSys will provide an additional treatment option for patients with ED.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts